Antengene scores $120 mln Series B


China-based Antengene Corporation, a clinical stage therapeutics company focused on oncology, has secured $120 million in Series B financing. Boyu Capital and FountainVest led the round with participation from Celgene Corporation, WuXi Corporate Venture Fund, Taikang, Qiming Venture Partners and TF Capital.

Source: Press Release